Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma
Summary. Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity of the drug and to...
Gespeichert in:
| Datum: | 2023 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
PH Akademperiodyka
2023
|
| Schlagworte: | |
| Online Zugang: | https://exp-oncology.com.ua/index.php/Exp/article/view/2019-2-4 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Experimental Oncology |
Institution
Experimental Oncology| id |
oai:ojs2.ex.aqua-time.com.ua:article-245 |
|---|---|
| record_format |
ojs |
| institution |
Experimental Oncology |
| baseUrl_str |
|
| datestamp_date |
2023-10-11T16:41:24Z |
| collection |
OJS |
| language |
English |
| topic |
C60 fullerene cisplatin hematological indices Lewis lung carcinoma tumor-bearing mice survival С60-Cis-Pt nanocomplex |
| spellingShingle |
C60 fullerene cisplatin hematological indices Lewis lung carcinoma tumor-bearing mice survival С60-Cis-Pt nanocomplex Prylutska, S.V. Lynchak, O.V. Kostjukov, V.V. Evstigneev, M.P. Remeniak, O.V. Rybalchenko, V.K. Prylutskyy, Yu.I. Ritter, U. Scharff, P. Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| topic_facet |
C60 fullerene cisplatin hematological indices Lewis lung carcinoma tumor-bearing mice survival С60-Cis-Pt nanocomplex C60 fullerene cisplatin hematological indices Lewis lung carcinoma tumor-bearing mice survival С60-Cis-Pt nanocomplex |
| format |
Article |
| author |
Prylutska, S.V. Lynchak, O.V. Kostjukov, V.V. Evstigneev, M.P. Remeniak, O.V. Rybalchenko, V.K. Prylutskyy, Yu.I. Ritter, U. Scharff, P. |
| author_facet |
Prylutska, S.V. Lynchak, O.V. Kostjukov, V.V. Evstigneev, M.P. Remeniak, O.V. Rybalchenko, V.K. Prylutskyy, Yu.I. Ritter, U. Scharff, P. |
| author_sort |
Prylutska, S.V. |
| title |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| title_short |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| title_full |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| title_fullStr |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| title_full_unstemmed |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| title_sort |
antitumor effects and hematotoxicity of c60-cis-pt nanocomplex in mice with lewis lung carcinoma |
| title_alt |
Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma |
| description |
Summary. Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity of the drug and to reduce its side toxic effects. Aim: To estimate the antitumor effects of С60-Cis-Pt nanocomplex in Lewis lung carcinoma (LLC) and analyze hematological toxicity in tumor-bearing mice. Materials and Methods: Complexation of C60 fullerene and Cis-Pt molecule was studied by computer simulation. С60-Cis-Pt nanocomplex was i.p. injected to LLC-bearing mice in a total dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/kg). The survival of tumor-bearing mice and the relative reduction of tumor weight was recorded. Blood indices were determined using the Particle Counter PCE210 automatic hematology analyzer. Results: Computer simulation demonstrated the formation of С60-Cis-Pt nanocomplex in physiological medium and its stability due to the hydrophobic interactions. Treatment with C60-Cis-Pt nanocomplex increased survival time of LLC-bearing mice by 32%, normalized hemoglobin content (up to 100 g/l), erythrocyte and platelet count as compared to the untreated LLC-bearing mice. Tumor weight decreased by 35.5%; the mitotic index of tumor cells decreased by 78%, and apoptotic index increased by 75%. The revealed effects of the C60-Cis-Pt nanocomplex were more pronounced than the effects of Cis-Pt or C60 fullerene alone in equivalent dose. Conclusion: Treatment with C60-Cis-Pt nanocomplex prolonged the survival of LLC-bearing mice and reduced anemia in LLC-bearing mice. |
| publisher |
PH Akademperiodyka |
| publishDate |
2023 |
| url |
https://exp-oncology.com.ua/index.php/Exp/article/view/2019-2-4 |
| work_keys_str_mv |
AT prylutskasv antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT lynchakov antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT kostjukovvv antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT evstigneevmp antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT remeniakov antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT rybalchenkovk antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT prylutskyyyui antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT ritteru antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma AT scharffp antitumoreffectsandhematotoxicityofc60cisptnanocomplexinmicewithlewislungcarcinoma |
| first_indexed |
2025-07-17T12:16:58Z |
| last_indexed |
2025-07-17T12:16:58Z |
| _version_ |
1850411276523536384 |
| spelling |
oai:ojs2.ex.aqua-time.com.ua:article-2452023-10-11T16:41:24Z Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma Prylutska, S.V. Lynchak, O.V. Kostjukov, V.V. Evstigneev, M.P. Remeniak, O.V. Rybalchenko, V.K. Prylutskyy, Yu.I. Ritter, U. Scharff, P. C60 fullerene, cisplatin, hematological indices, Lewis lung carcinoma, tumor-bearing mice survival, С60-Cis-Pt nanocomplex C60 fullerene, cisplatin, hematological indices, Lewis lung carcinoma, tumor-bearing mice survival, С60-Cis-Pt nanocomplex Summary. Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity of the drug and to reduce its side toxic effects. Aim: To estimate the antitumor effects of С60-Cis-Pt nanocomplex in Lewis lung carcinoma (LLC) and analyze hematological toxicity in tumor-bearing mice. Materials and Methods: Complexation of C60 fullerene and Cis-Pt molecule was studied by computer simulation. С60-Cis-Pt nanocomplex was i.p. injected to LLC-bearing mice in a total dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/kg). The survival of tumor-bearing mice and the relative reduction of tumor weight was recorded. Blood indices were determined using the Particle Counter PCE210 automatic hematology analyzer. Results: Computer simulation demonstrated the formation of С60-Cis-Pt nanocomplex in physiological medium and its stability due to the hydrophobic interactions. Treatment with C60-Cis-Pt nanocomplex increased survival time of LLC-bearing mice by 32%, normalized hemoglobin content (up to 100 g/l), erythrocyte and platelet count as compared to the untreated LLC-bearing mice. Tumor weight decreased by 35.5%; the mitotic index of tumor cells decreased by 78%, and apoptotic index increased by 75%. The revealed effects of the C60-Cis-Pt nanocomplex were more pronounced than the effects of Cis-Pt or C60 fullerene alone in equivalent dose. Conclusion: Treatment with C60-Cis-Pt nanocomplex prolonged the survival of LLC-bearing mice and reduced anemia in LLC-bearing mice. Summary. Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity of the drug and to reduce its side toxic effects. Aim: To estimate the antitumor effects of С60-Cis-Pt nanocomplex in Lewis lung carcinoma (LLC) and analyze hematological toxicity in tumor-bearing mice. Materials and Methods: Complexation of C60 fullerene and Cis-Pt molecule was studied by computer simulation. С60-Cis-Pt nanocomplex was i.p. injected to LLC-bearing mice in a total dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/kg). The survival of tumor-bearing mice and the relative reduction of tumor weight was recorded. Blood indices were determined using the Particle Counter PCE210 automatic hematology analyzer. Results: Computer simulation demonstrated the formation of С60-Cis-Pt nanocomplex in physiological medium and its stability due to the hydrophobic interactions. Treatment with C60-Cis-Pt nanocomplex increased survival time of LLC-bearing mice by 32%, normalized hemoglobin content (up to 100 g/l), erythrocyte and platelet count as compared to the untreated LLC-bearing mice. Tumor weight decreased by 35.5%; the mitotic index of tumor cells decreased by 78%, and apoptotic index increased by 75%. The revealed effects of the C60-Cis-Pt nanocomplex were more pronounced than the effects of Cis-Pt or C60 fullerene alone in equivalent dose. Conclusion: Treatment with C60-Cis-Pt nanocomplex prolonged the survival of LLC-bearing mice and reduced anemia in LLC-bearing mice. PH Akademperiodyka 2023-06-05 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2019-2-4 10.32471/exp-oncology.2312-8852.vol-41-no-2.13030 Experimental Oncology; Vol. 41 No. 2 (2019): Experimental Oncology; 106-111 Експериментальна онкологія; Том 41 № 2 (2019): Експериментальна онкологія; 106-111 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-41-no-2 en https://exp-oncology.com.ua/index.php/Exp/article/view/2019-2-4/2019-2-4 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/ |